Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

20151,381 citationsJournal Articlebronze Open Access

Authors

Himal Lal · Millennium Engineering and Integration (United States)

Anthony L. Cunningham · University of Sydney

Olivier Godeaux · GlaxoSmithKline (Belgium)

Roman Chlíbek · University of Defence

Javier Díez‐Domingo · Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana

Shinn‐Jang Hwang · Taipei Veterans General Hospital

Myron J. Levin

Abstract

The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older. Vaccine efficacy in adults who were 70 years of age or older was similar to that in the other two age groups. (Funded by GlaxoSmithKline Biologicals; ZOE-50 ClinicalTrials.gov number, NCT01165177.).

Topics & Keywords

Herpesvirus Infections and Treatments Rabies epidemiology and control Poxvirus research and outbreaks

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 22, pp. 2087-2096

DOI: 10.1056/nejmoa1501184

Field-Weighted Citation Impact: 85.99